News

Dear Doctor: How much help can people with coronary artery disease get from taking aspirin?
Zetia keeps your body from absorbing cholesterol in your diet, and it is generally safe and well-tolerated. So, it’s a good ...
USA Today15d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - USA TODAY
Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025 ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire ...
Lexington Herald Leader14d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Lexington Herald Leader
ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, ... Phase 1 Study Design. ... (approximately two 81 mg aspirin tablets).
Sacramento Bee14d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - The Sacramento Bee
ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, ... Phase 1 Study Design. ... (approximately two 81 mg aspirin tablets).
Pharmabiz12d
Aspire Biopharma enrolls last patient in phase 1 trial of its oral transmucosal fast-acting high-dose aspirin formulation
Aspire Biopharma enrolls last patient in phase 1 trial of its oral transmucosal fast-acting high-dose aspirin formulation: Estero, Florida Thursday, June 26, 2025, 18:00 Hrs [IST] ...
app.com15d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, ... Phase 1 Study Design. ... (approximately two 81 mg aspirin tablets).
Yahoo Finance14d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Yahoo Finance
ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery ...
Fort Worth Star-Telegram14d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Fort Worth Star ...
ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, ... Phase 1 Study Design. ... (approximately two 81 mg aspirin tablets).
The Fresno Bee14d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - The Fresno Bee
ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, ... Phase 1 Study Design. ... (approximately two 81 mg aspirin tablets).
Tri-City Herald14d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Tri-City Herald
ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, ... Phase 1 Study Design. ... (approximately two 81 mg aspirin tablets).